Metabonomics study of liver cancer based on ultra performance liquid chromatography coupled to mass spectrometry with HILIC and RPLC separations

Chen, Jing; Wang, Wenzhao; Lv, Shen; Yin, Peiyuan; Zhao, Xinjie; Lü, Xin; Zhang, Fengxia; Xu, Guowang

doi:10.1016/j.aca.2009.03.039

Cited by 198 publications

(142 citation statements)

References 26 publications

Supporting

Mentioning

134

Contrasting

Unclassified

Order By: Relevance

“…Numerous disorders have been described that lead to disturbances in energy production and intermediary metabolism, which are characterized by the abnormal levels of acylcarnitines (36 -40). For example, four identical acylcarnitines (carnitine C8:1, C9:1, C9:0 and C10:1) have been found as potential biomarkers in liver cancer patients (37). This also implies a single metabolite will have limited use for an accurate diagnosis of ESCC, however, the biomarker panel would be more specificity.…”

Section: Discussionmentioning

confidence: 99%

“…For example, the carnitine was demonstrated up-regulated in colorectal cancer (36) and liver cancer (37), whereas the carnitine 9:0 (m/z 302) was down-regulated in liver cancer (37). However, the opposite change has been observed in patients with inflammatory disorders: nonesterified carnitine was extremely decreased, while acylcarnitines were significantly increased in patient plasma (39).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Global and Targeted Metabolomics of Esophageal Squamous Cell Carcinoma Discovers Potential Diagnostic and Therapeutic Biomarkers

Chen

Zhang

et al. 2013

Molecular & Cellular Proteomics

114

View full text Add to dashboard Cite

Diagnostic and therapeutic biomarkers useful for esophageal squamous cell carcinoma (ESCC) have the ability to increase the long term survival of cancer patients. A metabolomics study, using plasma from four groups including ESCC patients before, during, and after chemoradiotherapy (CRT) and healthy controls, was originally carried out by LC-MS to determine global alterations in the metabolic profiles and find biomarkers potentially applicable to diagnosis and monitoring treatment effects. It is worth pointing out that a clear clustering and separation of metabolic data from the four groups was observed, which indicated that disease status and treatment intervention resulted in specific metabolic perturbations in the patients. A series of metabolites were found to be significantly altered in ESCC patients versus healthy controls and in pre-versus post-treatment patients based on multivariate statistical data analysis (MVDA). To further validate the reliability of these potential biomarkers, an independent validation was performed by using the selected reaction monitoring (SRM) based targeted approach. Finally, 18 most significantly altered plasma metabolites in ESCC patients, relative to healthy controls, were tentatively identified as lysophosphatidylcholines (lysoPCs), fatty acids, L-carnitine, acylcarnitines, organic acids, and a sterol metabolite. The classification performance of these metabolites were analyzed by receiver operating characteristic (ROC) 1 analysis and a biomarker panel was generated. Together, biological significance of these metabolites was discussed. Comparison between pre-and post-treatment patients generated 11 metabolites as potential therapeutic biomarkers that were tentatively identified as amino acids, acylcarnitines, and lysoPCs. Levels of three of these (octanoylcarnitine, lysoPC(16:1), and decanoylcarnitine) were closely correlated with treatment effect. Moreover, variation of these three potential biomarkers was investigated over the treatment course. The results suggest that these biomarkers may be useful in diagnosis, as well as in monitoring therapeutic responses and predicting outcomes of the ESCC. Molecular & Cellular Proteomics

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Global and Targeted Metabolomics of Esophageal Squamous Cell Carcinoma Discovers Potential Diagnostic and Therapeutic Biomarkers

Chen

Zhang

et al. 2013

Molecular & Cellular Proteomics

114

View full text Add to dashboard Cite

show abstract

“…To correct enrichment factors for different samples and the MS shift during long analysis duration, the data of each sample were normalized to the total area. Another advantage of normalizing to the total area is that inaccuracies caused by injection can be eliminated (25). After correction, the data were exported to SIMCA-P v11.5 software (Umetrics AB, Sweden) for multivariate data analysis.…”

Section: Methodsmentioning

confidence: 99%

Bladder Cancer Determination Via Two Urinary Metabolites: A Biomarker Pattern Approach

Huang

Lin

Gao

et al. 2011

Molecular & Cellular Proteomics

124

View full text Add to dashboard Cite

The purpose of this study was to use metabonomic profiling to identify a potential specific biomarker pattern in urine as a noninvasive bladder cancer (BC) detection strategy. A liquid chromatography-mass spectrometry based method, which utilized both reversed phase liquid chromatography and hydrophilic interaction chromatography separations, was performed, followed by multivariate data analysis to discriminate the global urine profiles of 27 BC patients and 32 healthy controls. Data from both columns were combined, and this combination proved to be effective and reliable for partial least squares-discriminant analysis. Following a critical selection criterion, several metabolites showing significant differences in expression levels were detected. Receiver operating characteristic analysis was used for the evaluation of potential biomarkers. Carnitine C9:1 and component I, were combined as a biomarker pattern, with a sensitivity and specificity up to 92.6% and 96.9%, respectively, for all patients and 90.5% and 96.9%, respectively for lowgrade BC patients. Metabolic pathways of component I and carnitine C9:1 are discussed. These results indicate that metabonomics is a practicable tool for BC diagnosis given its high efficacy and economization. The combined biomarker pattern showed better performance than single metabolite in discriminating bladder cancer

show abstract

“…2) and 21 metabolites were considered as potential biomarkers. Urinary metabolites related to arginine and proline metabolism, alanine and aspartate metabolism, lysine degradation, fatty acid oxidation, nicotinate and nicotinamide metabolism were significantly changed in HCC patients [34]. UPLC-based urinary metabonomics was used to explore common and specific metabolites in HCC patients with hepatitis B virus (HBV) or hepatitis C virus (HCV) infections.…”

Section: Hepatocarcinoma (Hcc) Liver Cirrhosis and Chronic Liver Dismentioning

confidence: 99%

UPLC-based metabonomic applications for discovering biomarkers of diseases in clinical chemistry

Zhao

Cheng

Vaziri

et al. 2014

Clinical Biochemistry

120

View full text Add to dashboard Cite

a b s t r a c t a r t i c l e i n f oObjectives: Metabonomics is a powerful and promising analytic tool that allows assessment of global lowmolecular-weight metabolites in biological systems. It has a great potential for identifying useful biomarkers for early diagnosis, prognosis and assessment of therapeutic interventions in clinical practice. The aim of this review is to provide a brief summary of the recent advances in UPLC-based metabonomic approach for biomarker discovery in a variety of diseases, and to discuss their significance in clinical chemistry.Design and methods: All the available information on UPLC-based metabonomic applications for discovering biomarkers of diseases were collected via a library and electronic search (using Web of Science, Pubmed, ScienceDirect, Springer, Google Scholar, etc.).Results: Metabonomics has been used in clinical chemistry to identify and evaluate potential biomarkers and therapeutic targets in various diseases affecting the liver (hepatocarcinoma and liver cirrhosis), lung (lung cancer and pneumonia), gastrointestinal tract (colorectal cancer) and urogenital tract (prostate cancer, ovarian cancer and chronic kidney disease), as well as metabolic diseases (diabetes) and neuropsychiatric disorders (Alzheimer's disease and schizophrenia), etc.Conclusions: The information provided highlights the potential value of determination of endogenous lowmolecular-weight metabolites and the advantages and potential drawbacks of the application of UPLC-based metabonomics in clinical setting.

show abstract

Metabonomics study of liver cancer based on ultra performance liquid chromatography coupled to mass spectrometry with HILIC and RPLC separations

Cited by 198 publications

References 26 publications

Global and Targeted Metabolomics of Esophageal Squamous Cell Carcinoma Discovers Potential Diagnostic and Therapeutic Biomarkers

Global and Targeted Metabolomics of Esophageal Squamous Cell Carcinoma Discovers Potential Diagnostic and Therapeutic Biomarkers

Bladder Cancer Determination Via Two Urinary Metabolites: A Biomarker Pattern Approach

UPLC-based metabonomic applications for discovering biomarkers of diseases in clinical chemistry

Contact Info

Product

Resources

About